Healthcare and life sciences rarely dominate the FTSE 250 in the way banks, housebuilders or miners do, yet the mid-cap index quietly hosts some of Britain's most distinctive businesses in the field. Three of them are in the spotlight this September for very different reasons. Genus, a world leader in animal genetics, has just reported a year of sharply higher profit and set out a fresh buyback. CVS Group, one of the UK's largest veterinary chains, is bedding in a move to the Main Market and a fast-growing Australian arm even as regulators scrutinise the sector. And Spire Healthcare, the country's second-largest private hospital operator, has agreed a billion-pound Takeover that would remove it from public markets altogether. Together they show how varied the "healthcare and life sciences" label can be, from pig and cattle breeding to companion-animal care and acute surgery.

Genus (LSE:GNS)

Genus sits at an unusual intersection of biology and agriculture. Through its PIC porcine division and ABS bovine business, it supplies breeding animals, semen and embryos to pig and cattle producers in more than 25 countries, using genomics to improve traits such as feed efficiency and disease resistance.

Results for the year ended 30 June 2026, published on 10 September, showed the strategy paying off on the Bottom Line even as the Top Line eased. Revenue slipped 2% to £658.1m, but adjusted pre-tax profit jumped 35% to £100.2m, with adjusted Earnings Per Share up by the same proportion to 110.3p. Both PIC and ABS lifted adjusted operating profit by 17%, to £130.8m and £22.9m respectively. The board raised the full-year Dividend 10% to 35.2p and flagged a £60m share buyback for the coming year, helped by a sharp fall in net Debt to £71.8m from £228.2m and free Cash Flow of £62m.

Two structural themes stand out. The first is China, where Genus has formed a 49%-owned porcine joint venture with Beijing Capital Agribusiness & Foods Group, opening the world's largest pork market more fully to its genetics. The second is its gene-edited, PRRS-resistant pig, which won US regulatory approval in 2025 and could become a long-term Royalty engine if adopted at scale. Investors were more cautious on the near term, however: the shares slipped after management guided to only moderate profit growth in the 2027 financial year, weighted to the second half.

CVS Group (LSE:CVSG)

CVS Group is a very different kind of healthcare company: it runs veterinary practices, diagnostic laboratories, pet crematoria and an online dispensary across the UK and, increasingly, Australia. It spent years as one of the largest companies on London's junior AIM market before stepping up to the Main Market, a move that qualified it for the FTSE 250 Index and broadened its investor base.

The most recent trading update, covering the year to 30 June 2026, reported total revenue of £712.8m, up 5.9%. Like-for-like growth of 2.1% was still below the group's 4-8% medium-term target, a reminder that UK pet-owner Demand has cooled from the pandemic-era boom. The standout was Australia, where revenue surged almost 52% to £79.1m and now accounts for roughly 11% of the group; UK revenue of £633.7m grew about 2%, an improvement on the prior year. Earlier in 2026 the company refinanced, launched a buyback and made an acquisition, and it announced the retirement of its long-serving chief executive.

One overhang is regulation. The Competition and Markets Authority has been investigating the UK veterinary sector, and CVS has formally responded to the watchdog's findings. Any remedies could reshape pricing and transparency across the industry, so the review remains a genuine swing factor.

Spire Healthcare (LSE:SPI)

Spire Healthcare tells the most dramatic story of the three. The company operates 38 private hospitals and more than 55 clinics across England, Wales and Scotland, treating over 1.36 million patients a year alongside a growing occupational-health arm, and works with more than 8,800 consultants.

On 7 September the board unanimously recommended a 250p-per-share cash offer from Tulip UK Bidco, a consortium of Toscafund, Three Hills and Ares. The deal values Spire's Equity at about £1.03bn and the enterprise at roughly £2.3bn, equivalent to 8.6 times its 2025 adjusted EBITDA, and represents a 66.2% premium to the 150.4p at which the shares traded on 13 May 2026, the day before bid speculation emerged. Structured as a court-sanctioned scheme of arrangement, it is expected to complete in the fourth quarter of 2026 or the first quarter of 2027, after which Spire would leave the stock market.

For now Spire remains a FTSE 250 constituent, but the takeover changes how investors should read it. The share price is anchored to the offer terms rather than to trading momentum, and a management reshuffle is already under way, with chief executive Justin Ash set to retire as part of the transition.

How the Three Companies Compare

The three illustrate three phases of a public-company life cycle. Genus is the established compounder, using cash generation to fund Buybacks and long-dated bets such as gene editing and China. CVS is the mid-cycle grower, recently promoted to the FTSE 250 and leaning on overseas expansion while navigating a domestic slowdown and regulatory scrutiny. Spire is the exit story, where private-equity capital has judged the Assets worth more off-market than on it.

They also show how loosely the "healthcare" label fits the mid-cap index. Only Spire treats human patients directly; Genus and CVS are, in effect, plays on animals and the Economics of protein production and pet ownership. What unites them is defensive demand, since food production, pet care and elective surgery all tend to hold up through the cycle, plus a reliance on scale, data and reputation.

What to Watch Next

For Genus, the questions are whether the Chinese joint venture scales as hoped, how quickly the PRRS-resistant pig moves from approval to commercial royalties, and whether the cautious 2027 guidance proves conservative. For CVS, watch UK like-for-like trends, the pace of Australian expansion and, crucially, the outcome of the CMA's work, which could impose new rules on pricing and disclosure. For Spire, the calendar now revolves around the scheme timetable, including Shareholder and court approvals and any rival approach, although a higher bid looks unlikely given the board's unanimous backing.

Taken together, these three FTSE 250 names capture the breadth of British healthcare investing in September 2026: a cash-generative genetics leader, an acquisitive vet group finding its feet on the Main Market, and a hospital operator on the cusp of going private. Each faces a distinct set of risks, from guidance and regulation to deal completion, and each rewards close reading rather than a single headline.